Skip to main content

Month: February 2026

Natural Alternatives International, Inc. Announces 2026 Q2 and YTD Results

CARLSBAD, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $2.6 million, or $0.42 per diluted share, on net sales of $34.8 million for the second quarter of fiscal year 2026 compared to a net loss of $2.2 million, or $0.37 per diluted share, in the second quarter of the prior fiscal year. Net sales during the three months ended December 31, 2025, increased $0.7 million, or 2%, to $34.8 million as compared to $34.1 million recorded in the comparable prior year period. During the same period, private-label contract manufacturing sales increased 2% to $32.8 million. Private-label contract manufacturing sales increased primarily due to increased orders...

Continue reading

Ambow Files Annual Report on Form 10-K for Fiscal Year 2025

CUPERTINO, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) — Ambow Education Holding Ltd. (“Ambow” or the “Company”) (NYSE American: AMBO), a global innovator of AI-powered phygital (physical + digital) solutions for education, conferencing and events, today announced that it has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 with the Securities and Exchange Commission (the “SEC”). The Annual Report on Form 10-K can be accessed on the Company’s investor relations website at https://www.ambow.com and the SEC’s website at https://www.sec.gov. Shareholders and ADS holders may request a hard copy of the Annual Report containing its audited consolidated financial statements, free of charge, at ir@ambow.com or by mail at Ambow Education Holding Ltd., 10080 N. Wolfe RD, Suite SW3-200, Cupertino, CA 95014, USA. About...

Continue reading

HCM IV Acquisition Corp. Announces Closing of $287,500,000 Initial Public Offering

NORWALK, Ct, Feb. 13, 2026 (GLOBE NEWSWIRE) — HCM IV Acquisition Corp. (Nasdaq: HACQU) (the “Company”), a blank check company whose business purpose is to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, announced today the closing of its previously announced initial public offering of 28,750,000 units, including 3,750,000 units issued pursuant to the full exercise by the underwriter of its over-allotment option. The units were sold at a price of $10.00 per unit. The Company’s units began trading on February 12, 2026 on the Nasdaq Global Market under the symbol “HACQU”. Each unit consists of one Class A ordinary share and one-fourth of one redeemable warrant. Each whole warrant is exercisable to purchase one Class A ordinary...

Continue reading

Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

Joshua HareJoshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, LongeveronMr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborations Corporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue his work in the Company’s on-going business development activitiesMIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology...

Continue reading

CEA Industries (BNC) Issues Statement Refuting YZi Labs’ Latest False and Reckless Claims

Confirms BNC is fully compliant with Nasdaq rules for holding the annual meeting LOUISVILLE, CO, Feb. 13, 2026 (GLOBE NEWSWIRE) — CEA Industries Inc. (NASDAQ: BNC) (“BNC” or the “Company”), a growth-oriented company focused on managing the world’s largest corporate treasury of BNB token, today responded to false claims made by YZILabs Management Ltd. (“YZi Labs”) about the Company’s compliance with Nasdaq Stock Market (“Nasdaq”) rules regarding the date of the Company’s Annual Meeting of Stockholders (the “Annual Meeting”): BNC is in full compliance with Nasdaq Rule 5620(a). Nasdaq rules also allow the Company to submit a plan to regain compliance if the Annual Meeting has not been held by the fiscal year end. Given that our fiscal year does not even end for two more months, YZi Labs’ reckless claim that the Company is at risk...

Continue reading

Inotiv Provides Notice Regarding Cybersecurity Incident

WEST LAFAYETTE, Ind., Feb. 13, 2026 (GLOBE NEWSWIRE) — Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, is providing public notice regarding its cybersecurity incident that it became aware of on August 8, 2025. As previously described in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on August 18, 2025 and its subsequent SEC filings, Inotiv experienced a cybersecurity incident in early August 2025. While Inotiv currently has no indication that personal information has been misused, it has provided notice via mail and email, and via this release and an accompanying posting on its website,...

Continue reading

Heartflow to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026

MOUNTAIN VIEW, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) — Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the fourth quarter and full year of 2025 after market close on Wednesday, March 18, 2026. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on March 18, 2026. Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a unique PIN to join the call. Participants are encouraged to register more than 15 minutes prior to the start of the call. A live and archived webcast of the event will also be available on the “Investor Relations” section of the Heartflow website...

Continue reading

Edesa Biotech Reports Fiscal 1st Quarter 2026 Results

TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) — Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three months ended December 31, 2025 and provided an update on its business. During the first quarter, Edesa progressed manufacturing of its dermatology drug candidate, EB06 (an anti-CXCL10 monoclonal antibody), and placebo for an upcoming Phase 2 study in moderate-to-severe nonsegmental vitiligo. The company anticipates recruitment will begin midyear 2026, subject to regulatory approvals. In its respiratory program, Edesa reported that it is evaluating subgroup data for additional efficacy signals among subjects with certain comorbidities following positive results from a Phase 3 study of...

Continue reading

Farmer Brothers Coffee Reports Second Quarter Fiscal 2026 Financial Results

FORT WORTH, Texas, Feb. 13, 2026 (GLOBE NEWSWIRE) — Farmer Brothers Coffee Co. (NASDAQ: FARM), a leading roaster, wholesaler and distributor of coffee, tea and allied products, announced today its second quarter fiscal 2026 financial results for the period ended Dec. 31, 2025. The company filed its Form 10-Q, which will be posted on the Investor Relations section of its website after the close of market Friday, Feb. 13. “As expected, the second quarter was a challenging one for Farmer Brothers. We, however, continued to see year-over-year improvement in selling and general and administrative cost and our gross margin remained above 35%, where we expect it to be for the remainder of fiscal 2026,” said President and Chief Executive Officer John Moore. “Despite pressures related to higher cost of goods sold and current micro and macroeconomic...

Continue reading

Westwood Holdings Group Reports Fourth Quarter and Full Year 2025 Results

Our expanded ETF platform now exceeds $200 million in AUMSuccessful year-end close of WES II with over $300 million in commitmentsManaged Investment Solutions team secured its first institutional client DALLAS, Feb. 13, 2026 (GLOBE NEWSWIRE) — Westwood Holdings Group, Inc. (NYSE: WHG) today reported fourth quarter and fiscal year 2025 earnings. Significant items include:Investment strategies beating their primary benchmarks in the fourth quarter included Enhanced Balanced, Total Return, Income Opportunity, Multi-Asset Income, Alternative Income, MLP & Energy Infrastructure, Westwood Salient Enhanced Midstream Income ETF and Westwood Salient Enhanced Energy Income ETF. Income Opportunity posted a top quartile ranking vs. peers and Total Return posted a top decile ranking in the quarter. Quarterly revenues totaled $27.1 million...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.